Last reviewed 2026-05-14 · How we verify

Isoniazid Prevention Therapy

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Joint pain
• Skin rashes
• Headache
• Weakness
• Fever
• Numbness, tingling, burning, or pain in hands and feet
• Stomach pain
• Hepatotoxicity
• Loss of appetite
• Diarrhea
• Unusual tiredness or weakness
• Other

Key clinical trials

• An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM (PHASE3)
• Asymptomatic TB With Innovative Modified Short-course Regimens (PHASE4)
• Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings (NA)
• ThiPhiSA: New Pathways to Prevention From Community TB Screening in South Africa (NA)
• Window Prophylaxis for Pediatric Tuberculosis Prevention Trial (NA)
• Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients (PHASE4)
• Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV (PHASE1, PHASE2)
• Comparison of the Outcome of Treatment With Silymarin or N-Aceylcysteine in Patients Taking Anti-Tuberculous Drugs for Tuberculosis at a Tertiary Care Hospital , Karachi (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Isoniazid Prevention Therapy CI brief — competitive landscape report
• Isoniazid Prevention Therapy updates RSS · CI watch RSS
• Columbia University portfolio CI